

Colorectal Cancer Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Stage: __0 __I __IIA __IIB __IIC __IIIA __IIIB __IIIC __IVA __IVB __ Recurrent

Line of Treatment: __Neoadjuvant/Pre-Op __ Adjuvant/Post-Op __First Line __Second Line __Third Line __Third Line+

ECOG Performance Status: __0 __1 __2 __3 __4

Biomarker:

RAS: __Wild type __Mutant

Adjuvant Therapy*

Capecitabine (Xeloda)

FLOX†: fluorouracil (5FU), leucovorin and oxaliplatin (Eloxatin)

FULV: fluorouracil (5FU) and leucovorin

Modified FOLFOX-6‡: fluorouracil (5FU), leucovorin and oxaliplatin (Eloxatin)

Metastatic disease | RAS Wild Type (WT) or Mutant (MT)‡ | 1st or 2nd line therapy

Capecitabine (Xeloda)

FOLFIRI: fluorouracil (5FU), leucovorin, and irinotecan (Camptosar)

FOLFIRI: fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and bevacizumab (Avastin)

FOLFOXIRI: fluorouracil (5FU), leucovorin, irinotecan (Camptosar), oxaliplatin (Eloxatin), and bevacizumab (Avastin)

FULV: fluorouracil (5FU) and leucovorin

FULV: fluorouracil (5FU), leucovorin and bevacizumab (Avastin)

Modified FOLFOX-6: fluorouracil (5FU), leucovorin, and oxaliplatin (Eloxatin)

Modified FOLFOX-6: fluorouracil (5FU), leucovorin, oxaliplatin (Eloxatin), and bevacizumab (Avastin)

Metastatic disease | RAS WT | 2nd line

FOLFIRI: fluorouracil (5FU), leucovorin, irinotecan (Camptosar) and panitumumab (Vectibix)

Irinotecan (Camptosar) and panitumumab (Vectibix)

Metastatic disease | RAS WT or MT‡ | 3rd line+

Trifluridine + tipiracil (Lonsurf)

Metastatic disease | RAS WT | 3rd line+

Irinotecan (Camptosar) and panitumumab (Vectibix)

Panitumumab (Vectibix) monotherapy

*Patients with stage II MSI-H (microsatellite instability - high) colorectal cancer are not included in the Adjuvant Pathway.

†Dose & sequence of administration differ between modified FOLFOX-6 and FLOX

‡Exon 2 KRAS, non-exon 2 KRAS, and NRAS mutations

